Agitation in Participants With Dementia of the Alzheimer's TypePhase 3NCT02442778
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
A Phase 3 study testing AVP-786-18, AVP-786-28 and AVP-786-42.63 in people with Agitation in Participants With Dementia of the Alzheimer's Type, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 83 sites in 2 countries.
Trial summary
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Agitation in Participants With Dementia of the Alzheimer's Type
- What is being tested?
- AVP-786-18, AVP-786-28 and AVP-786-42.63
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 522 participants
- Where
- 83 sitesin 2 countries
- Study dates
- 11 Nov 2015to 9 Sep 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
- The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
- The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
- Either out participants or residents of an assisted-living facility or a skilled nursing home
- Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is >=4 (moderately ill) at screening and baseline
- Mini-Mental State Examination (MMSE) score is between 6 and 26 (inclusive) at screening and baseline
- Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant.
Who cannot join
- Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
- Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
- Participant with myasthenia gravis
Trial locations and contacts
83 sites in 2 countries.
83 sites in 2 countries
United States79 sites
Daystar Clinical Research Inc
Akron, Ohio, 44313
Emory Brain Health Center
Atlanta, Georgia, 30329
JEM Research Institute
Atlantis, Florida, 33462
Heritage Valley Medical Group, Inc.
Beaver, Pennsylvania, 15009
Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic
Bennington, Vermont, 05201
Clinical Research Of Brandon, LLC
Brandon, Florida, 33511
Brooklyn Medical Institute
Brooklyn, New York, 11214
Integrative Clinical Trials, LLC
Brooklyn, New York, 11229
Meridien Research
Brooksville, Florida, 34601
Valley Medical Research
Centerville, Ohio, 45459
Brain and Spine Center
Chandler, Arizona, 85226
Herbert Harris, MD, PhD, PA
Chapel Hill, North Carolina, 27517
RH Johnson VA Medical Center
Charleston, South Carolina, 29401
ANI Neurology PLLC dba Alzheimer's Memory Center
Charlotte, North Carolina, 28270
Center for Emotional Fitness
Cherry Hill, New Jersey, 08002
CTI Clinical Research Center
Cincinnati, Ohio, 45212
Columbus Research & Wellness Institute, INC
Columbus, Georgia, 31904
Texas Neurology, P.A.
Dallas, Texas, 75214
Denver Neurological Research, LLC
Denver, Colorado, 80210
Moonshine Research Center, Inc
Doral, Florida, 33166
Science Connections, LLC
Doral, Florida, 33166
Michigan State University
East Lansing, Michigan, 48824
The Samuel & Alexia Bratton Memory Clinic
Easton, Maryland, 21601
Health Initiatives Research
Fayetteville, Arkansas, 72703
Behavioral Research Specialists, LLC
Glendale, California, 91206
Finlay Medical Research Corp
Greenacres City, Florida, 33467
Mir Neurology
Hagerstown, Maryland, 21742
Indago Research & Health Center, Inc.
Hialeah, Florida, 33012
New Life Medical Research Center, Inc.
Hialeah, Florida, 33012
Reliable Clinical Research,LLC
Hialeah, Florida, 33012
Research in Miami, Inc
Hialeah, Florida, 33013
The Research Center, Inc
Hialeah, Florida, 33013
Maxblue Institute
Hialeah, Florida, 33018
Baylor College of Medicine
Houston, Texas, 77030
Houston Methodist Neurological Institute
Houston, Texas, 77030
Clinical Trial Network
Houston, Texas, 77074
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana, 46256
Irvine Center for Clinical Research
Irvine, California, 92614
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, 32256
Alzheimer's Research and Treatment Center
Lake Worth, Florida, 33449
Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital
Lakewood, Ohio, 44107
The Birches at Newton / Family Medical Associates
Levittown, Pennsylvania, 19056
Premier Clinical Research Institute, Inc.
Miami, Florida, 33122
Project 4 Research
Miami, Florida, 33125
BioMed Research Institute
Miami, Florida, 33126
CCM Clinical Research Group
Miami, Florida, 33133
DADE Research Center, LLC
Miami, Florida, 33135
AMB Research Center, Inc.
Miami, Florida, 33144
United Health Research Corp
Miami, Florida, 33144
Advance Medical Research Center
Miami, Florida, 33165
Coral Research Clinic Corp
Miami, Florida, 33175
P&S Reasearch
Miami, Florida, 33175
The Neurology Research Group, LLC
Miami, Florida, 33176
Kendall Research Institute
Miami, Florida, 33183
Nuovida Research Center Corp.
Miami, Florida, 33186
The NeuroCognitive Institute
Mount Arlington, New Jersey, 07856
Collier Neurologic Specialists, LLC
Naples, Florida, 34102
Eastside Comprehensive Medical Center, LLC
New York, New York, 10128
Boston Center for Memory
Newton, Massachusetts, 02459
AMAC Research Institute
North Dartmouth, Massachusetts, 02747
Lazlo J. Mate, MD, PA
North Palm Beach, Florida, 33408
Compass Research, LLC
Orlando, Florida, 32806
IMIC Inc.
Palmetto Bay, Florida, 33157
California Neurological Services
Panorama City, California, 91402
Havana Research Institute
Pasadena, California, 91105
University of West Florida
Pensacola, Florida, 32514
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
Baptist Health Medical Group
Richmond, Kentucky, 40475
Veteran Affairs Medical Center, Salem Virginia
Salem, Virginia, 24153
Pharmaceuticals Research Associates, Inc.
Salt Lake City, Utah, 84107
Texas Medical Research Associates, L.L.C.
San Antonio, Texas, 78238
Pacific Research Network, Inc
San Diego, California, 92103
Syrentis Clinical Research
Santa Ana, California, 92705
BG Neurology
Spartanburg, South Carolina, 29307
Viking Clinical Research
Temecula, California, 92591
Territory Neurology & Research Institute
Tucson, Arizona, 85704
IPC Research
Waukesha, Wisconsin, 53188
Neurology Research Institute Palm Beach, LLC
West Palm Beach, Florida, 33407
Burke Rehabilitation Hospital
White Plains, New York, 10605
Canada4 sites
Dr. Alexander McIntyre Inc.
Calgary, Alberta, N7L 1C1
The Medical Art Health Research Group
Kelowna, Bristish Columbia
The Medical Art Health Research Group
Penticton, Bristish Columbia
The Medical Art Health Research Group
West Vancouver, Bristish Columbia
About this study
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.
Read the detailed description
Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.
This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.
Approximately 470 participants will be enrolled at approximately 75 centers in North America.
Study medication will be administered orally twice-daily from Day 1 through Week 12 (Day 85). Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.
- Being tested
- AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AVP-786-18Drug
18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
PlaceboDrug
Administered as capsules.
AVP-786-28Drug
28 mg of d6-DM and 4.9 mg of Q
AVP-786-42.63Drug
42.63 mg of d6-DM and 4.9 mg of Q
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks. Receives: Drug: Placebo |
| AVP-786-28 | Experimental | Participants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12. Receives: Drug: AVP-786-18; Drug: AVP-786-28 |
| AVP-786-42.63 | Experimental | Participants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12. Receives: Drug: AVP-786-28; Drug: AVP-786-42.63 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score
The CMAI was used to assess the frequency of manifestations of agitated behaviors in elderly participants. It consists of 29 agitated items rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Negative change from baseline indicates improvement. Mixed Model Repeated Measures (MMRM) was used for the analysis.
Measured: Baseline, Week 12
Secondary outcomes (17)
Relative Change From Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score
The mADCS-CGIC-Agitation is a modified version of the ADCS-CGIC containing additional questions related to agitation and an assessment of the Clinician's Impression of Change focused specifically on agitation. Participants are asked to rate their impression of change as: 1=Marked Improvement; 2=Moderate Improvement; 3=Minimal Improvement; 4=No Change; 5=Minimal Worsening; 6=Moderate Worsening; 7=Marked Worsening. Higher scores indicate worsening of agitation and positive change from baseline indicates worsening. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score
The NPI is a retrospective caregiver-informant interview covering 12 neuropsychiatric symptom domains. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable AD and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Agitation/Aggression Caregiver Distress Score
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as:1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12 with a higher score indicating worsening of symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12 with a higher score indicating worsening of symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score
The ZBI is a 22-item scale used to assess the impact of a participants' disabilities on the caregiver's life. It is designed to reflect the burden experienced by caregivers of dementia participants and can either be completed by the caregiver or administered as an interview. Each item of the scale is rated to reflect the burden using the 5-point scale: 0=Never; 1=Rarely; 2=Sometimes; 3=Quite Frequently; 4=Nearly Always. The ZBI is scored by summing the responses of the individual questions and ranges from 0 to 88. Higher scores indicate greater caregiver distress. Negative change from baseline indicates less distress. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Irritability/Lability Domain Score
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as:1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Total Score
NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, night time behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as:1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as:1=mild,2=moderate,3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all,1=minimal,2=mild,3=moderate,4=severe,5=very severe. Individual Item scores are added to yield a possible total score of 0 to 144. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score
The CGIS-Agitation is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1=normal, not at all ill participants; 7=among the most extremely ill participants) and is assessed for severity of agitation. A value of 0 is given to participants who are not assessed. Higher scores indicate poor health of participants. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating
The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score
The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Higher scores indicate less response to treatment. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score
The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. MMRM was used for the analysis.
Measured: Baseline, Week 12
Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score
The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0 (no depression) to 38 (maximum depression). Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression. MMRM was used for the analysis.
Measured: Baseline, Week 12
Number of Participants With the Change From Baseline in the General Medical Health Rating (GMHR) Score at Week 12
The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. MMRM was used for the analysis.
Measured: Week 12
Change From Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score
The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. Negative change from baseline indicates less cognitive impairment. MMRM method was used for analysis.
Measured: Baseline, Week 12
Resource Utilization in Dementia (RUD) Score: Number of Hours Per Day the Caregiver Spent Assisting the Participant
The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on hours per day the caregiver spent assisting participant were reported in this outcome measure, using the following questions:
Q1= On a typical care day during the last 30 days, how much time per day did you assist the participant with tasks such as toilet visits, eating, dressing, grooming, walking and bathing? Q2= On a typical care day during the last 30 days, how much time per day did you assist the participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters? Q3= On a typical care day during the last 30 days, how much time per day did you spend supervising (that is, preventing dangerous events) the participant?
Measured: Week 12
Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations, doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on days the caregiver spent assisting participant were reported in this outcome measure, using the following questions:
Q1= During the last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking and bathing) services to the participant? Q2= During the last 30 days, how many days did you spend providing these (shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters) services to the participant? Q3= During the last 30 days, how many days did you spend providing these services (supervising) to the participant?
Measured: Week 12
Resource Utilization in Dementia (RUD) Score: Number of Visits to Hospital, Emergency, and Healthcare Professional
The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations, doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on the number of hospital visits, emergency visits and visits to healthcare professional were reported in this outcome measure using the following questions:
Q1= During the last 30 days, how many times did the participant receive care in a hospital emergency room (for less than 24 hours)? Q2= During the last 30 days, how many times did the caregiver receive care in a hospital emergency room (for less than 24 hours)? Q3= During the last 30 days total number of visits by participant to a health care professional? Q4= During the last 30 days, how many times (number of visits for each) the participant visited any other health care professional?
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2015 (estimated)
- Study start11 Nov 2015
- Primary completion14 Aug 2019
- Study completion9 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Agitation in Participants With Dementia of the Alzheimer's TypeStudies of the same condition, open and under way.
- More trials run by Otsuka Pharmaceutical Development & Commercialization, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 522 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02442778
- Sponsor's protocol ID
- 15-AVP-786-302
- Status last verified
- Aug 2022
- First submitted
- 11 May 2015
- Last updated
- 9 Sep 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researcher sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- ClinicalTrials.gov ID
- NCT02442778
- Acronym / sponsor ID
- 15-AVP-786-302
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 522 participants (actual)
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Industry (pharma, biotech, devices)
- Study start
- 11 Nov 2015 (actual)
- Primary completion
- 14 Aug 2019 (actual)
- Study completion
- 9 Sep 2019 (actual)
- First posted
- 13 May 2015 (estimated)
- Results
- Posted 9 Sep 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.
Detailed description
Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.
This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.
Approximately 470 participants will be enrolled at approximately 75 centers in North America.
Study medication will be administered orally twice-daily from Day 1 through Week 12 (Day 85). Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboParticipants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks. |
| AVP-786-28 | Experimental | Drug: AVP-786-18, Drug: AVP-786-28Participants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12. |
| AVP-786-42.63 | Experimental | Drug: AVP-786-28, Drug: AVP-786-42.63Participants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12. |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
- The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
- The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
- Either out participants or residents of an assisted-living facility or a skilled nursing home
- Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is >=4 (moderately ill) at screening and baseline
Key exclusion criteria (3 listed)
- Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
- Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
- Participant with myasthenia gravis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AVP-786-1818 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q) | Drug | AVP-786-28 |
| PlaceboAdministered as capsules. | Drug | Placebo |
| AVP-786-2828 mg of d6-DM and 4.9 mg of Q | Drug | AVP-786-28, AVP-786-42.63 |
| AVP-786-42.6342.63 mg of d6-DM and 4.9 mg of Q | Drug | AVP-786-42.63 |
Primary outcome
Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score
Time frame: Baseline, Week 12
The CMAI was used to assess the frequency of manifestations of agitated behaviors in elderly participants. It consists of 29 agitated items rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Negative change from baseline indicates improvement. Mixed Model Repeated Measures (MMRM) was used for the analysis.
17 secondary outcomes
Relative Change From Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Agitation/Aggression Caregiver Distress Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Irritability/Lability Domain Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the NPI Total Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score
Time frame: Baseline, Week 12
Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score
Time frame: Baseline, Week 12
Number of Participants With the Change From Baseline in the General Medical Health Rating (GMHR) Score at Week 12
Time frame: Week 12
Change From Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score
Time frame: Baseline, Week 12
Resource Utilization in Dementia (RUD) Score: Number of Hours Per Day the Caregiver Spent Assisting the Participant
Time frame: Week 12
Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
Time frame: Week 12
Resource Utilization in Dementia (RUD) Score: Number of Visits to Hospital, Emergency, and Healthcare Professional
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researcher sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Related trials for Agitation in Participants With Dementia of the Alzheimer's Type
RecruitingPhase 2/3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Agitation, Alzheimer Disease
Active, not recruitingPhase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Alzheimer Disease, Agitation,Psychomotor
Active, not recruitingPhase 3
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Agitation, Alzheimer's Type Dementia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
83 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing AVP-786-18, AVP-786-28 and AVP-786-42.63 in people with Agitation in Participants With Dementia of the Alzheimer's Type, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 83 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 83 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2022.